VP2-2022: Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer

I Vergote ,J Sehouli,V Makker,B.J Monk,E Hamilton,Sharon Shacham ,Tomer Levy ,David Cibula ,Pauline Wimberger ,Danielle Miller ,Stephen Welch ,Giorgio Valabrega ,Giovanni Scambia ,Sabine Henry ,Toon Van Gorp ,Alejandro Pérez Fidalgo ,Mansoor Raza Mirza ,José Gil Martínez ,Eva María Guerra Alía ,Debra L Richardson

doi:10.1016/j.annonc.2022.02.223

Abstract

Patients (pts) with first-line metastatic or recurrent endometrial cancer (EC) are usually treated with paclitaxel and carboplatin but most have short-term disease control and a poor prognosis. Selinexor (SEL) inhibits XPO1 resulting in nuclear accumulation of p53, and has shown clinical activity in previously treated, advanced EC.

Full Text